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Abstract
Background: Hepatitis B virus (HBV) infection causes lipid metabolism disorders. Apolipoprotein A5 (ApoA5) is a
new apolipoprotein family member that plays an important role in the regulation of lipid metabolism. The present
study was to investigate the impact of HBV on ApoA5 expression and its regulatory mechanism.
Methods: Reverse transcription polymerase chain reaction (RT-PCR) and western blotting were used to measure
ApoA5 mRNA and protein expression in HepG2 and HepG2.2.15 cells. Enzyme-linked immunosorbent assay (ELISA)
was used to measure the serum ApoA5 levels in healthy individuals and HBV patients. HBV infectious clone pHBV1.3
or individual plasmids expressing the HBV genome was cotransfected with the ApoA5 promoter pGL3-Apo5-LUC
plasmid into HepG2 cells to assess the luciferase activity. RT-PCR and western blotting methods were used to
detect Apo5 mRNA and protein expression, respectively.
Results: The ApoA5 mRNA and protein expression levels were decreased in HepG2.2.15 cells compared with the
control HepG2 cells. The serum ApoA5 levels were 196.4 ± 28.7 μg/L in the healthy individuals and 104.5 ± 18.3 μg/L in
the HBV patients, statistical analysis showed that the ApoA5 levels were significantly lower in HBV patients than in the
healthy individuals (P < 0.05). pHBV1.3 and its core gene inhibited ApoA5 promoter activity and mRNA and protein
expression in HepG2 cells.
Conclusion: HBV inhibits ApoA5 expression at both the transcriptional and translational levels through its core gene.
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Background
Hepatitis B virus (HBV) is a DNA virus belonging to
Hepadnaviridae with a viral genome containing approxi-
mately 3200 base pairs. To date, there are approximately
350 million HBV carriers around the globe, and up to 50
million people are infected with HBV each year [1, 2].
The HBV genome contains approximately 3200 base
pairs and 4 open reading frames (S/PreS, C/PreC, P and X).
S/PreS encodes 3 surface proteins (PreS1, PreS2 and S),
C/PreC encodes the signal peptide and core protein
(PreC), P encodes the DNA polymerase (P), and X en-
codes the X protein (HBx) [3].
Apolipoprotein A5 (ApoA5) is a new member of the
apolipoprotein family and is specifically synthesized and
secreted by the liver. ApoA5 is present in high-density
lipoprotein (HDL), very low-density lipoprotein (VLDL)
and chylomicrons (CMs) but is not present in other
plasma lipoproteins [4]. Studies have shown that HBV
infection can cause blood lipid metabolism disorder [5].
However, there have been no reports concerning the re-
lationship between HBV and ApoA5. The present study
investigated the impact of HBV on ApoA5 expression
and explored its regulatory mechanism.
Methods
Study subjects
We collected 221 cases of clinically diagnosed HBV pa-
tients with an average age of 51.6 ± 11.8 years, of whom
120 were males and 101 were females. None of the patients
had diseases of the heart, brain, kidney or other important
organs, other chronic liver diseases, or diseases that could
cause metabolic disorders. A total of 125 healthy individuals
with an average age of 48.7 ± 13.6 years were used as the
normal control group, of whom 75 were males and 50 were
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females. The work was approved by the Ethical Committee
and written informed consents were obtained from all par-
ticipating individuals.
Cell culture and transfection
HepG2 and HepG2.2.15 cells were cultured in RPMI
1640 medium containing 10 % foetal bovine serum, 100
U/mL of penicillin and 100 mg/L of streptomycin in a
5 % CO2 and 37 °C incubator. Prior to transfection, the
HepG2 cells were seeded into 24-well or 6-well plates.
Cell transfection was performed according to the follow-
ing procedure. Plasmid DNA and 2 μL of Lipofectamine
2000 (Invitrogen, U.S.A) were diluted in 30 μL of RPMI-
1640, or 4 μg of plasmid DNA and 6 μL of Lipofectamine
2000 were diluted in 100 μL of RPMI-1640. The mixtures
were incubated at room temperature for 20 min. Then,
the prepared transfection mixture was added to the cell
culture medium in the 24-well or 6-well plates. The cells
were cultured in a CO2 incubator. The transfection effi-
ciency of HepG2 cells was evaluated by transfected with
pIRES2-EGFP.
Reverse Transcriptase (RT)-PCR detection
TRIzol R (Invitrogen, Carlsbad, CA, USA) was used to
isolate total cellular RNA. Reverse transcription was per-
formed to synthesize cDNA for use as a template. For
ApoA5 gene detection, the sense primer 5′ TGGGCTCT
GGCTCTTCTTT 3’ and the antisense primer 5′ ACCTCC
TCCAACTCCTCCTG 3’ were used for PCR amplification.
β-actin was used an internal control. The product was veri-
fied by 1 % agarose gel electrophoresis.
Measurement of luciferase activity
The transfected cells were cultured for 48 h. Then, the
cells were harvested, lysis buffer was added to lyse the
cells, and 10 μL of the cell lysate was mixed with 100 μL
of the luciferase substrate. A luminometer was used to
measure the luciferase activities [6].
Western blotting analysis
Transfected HepG2 cells were collected and lysed in lysis
buffer using sonication. The lysates were centrifuged to
collect the proteins in the supernatant. A 20 mg protein
sample was mixed with an equal volume of sample buffer.
The mixture was boiled in water for 5 min and loaded
onto a 12 % SDS-PAGE gel for separation. After electro-
phoresis, the proteins were transferred onto a nitrocellu-
lose (NC) membrane. The membrane was blocked with
5 % fat-free milk dissolved in phosphate-buffered saline
plus Tween 20 (PBST) for 2 h. ApoA5 monoclonal anti-
body (Santa Cruz Biotechnology Inc., Santa Cruz, CA,
diluted 1:1500) was added to the membrane and incu-
bated for 2 h. Then, the membrane was washed 3 times
with PBST, and a horseradish peroxidase-conjugated goat
anti-rabbit secondary antibody (Sigma, diluted 1:5000)
was added to the membrane and incubated for 1 h. The
membrane was washed 4 times with PBST. An electroche-
miluminescence (ECL) colouring system (Amersham Life
Sciences) was used to develop the blots.
Apolipoprotein A5 measurement
An enzyme-linked immunosorbent assay (ELISA) was
used for serum ApoA5 detection with a commercial
ELISA kit (LSBio).
Statistical analysis
The SPSS 16.0 statistical software package was used for
the data analysis. The data are presented as the mean ±
standard deviation (x ± s). The t test was used to com-
pare the serum ApoA5 levels between the control group




Baseline characteristics of the participants are shown in
Table 1. There were no significant differences in gender,
age and BMI between the HBV patient and healthy in-
dividuals (P > 0.05), and significant differences were
found between the two groups in terms of ALT and AST
(P < 0.001).
ApoA5 mRNA and protein expression was decreased in
HepG2.2.15 cells
HepG2.2.15 cells are HepG2 cells that stably transfected
with the HBV genome, and can express viral RNA and
protein, synthetise and secrete the complete virus-like
particles [7]. Using RT-PCR and western blotting, we ex-
amined ApoA5 expression in the HepG2 and HepG2.2.15
cells. As shown in Fig. 1, the ApoA5 mRNA and protein
expression in the HepG2.2.15 cells were significantly re-
duced compared with those in the HepG2 cells.
Table 1 Clinical and biochemical characteristics of the subjects
enrolled in the present study





Age (years) 48.7 ± 13.6 51.6 ± 11.8 0.126
Sex (male/female) 75/50 120/101 0.247
BMI 25.4 ± 1.8 24.9 ± 1.2 0.352
HBeAg (+/−) NS 47/174 ND
HBV DNA (copies/ml) <500 5.8E + 06 ± 4.2E + 08 ND
ALT (IU/l) <30 193.4 ± 187.5 <0.001
AST (IU/l) <30 185.8 ± 170.2 <0.001
A significant at p value ≤ 0.05
N number of the subjects, NS none sense, ND not done, BMI body mass index,
ALT alkanine aminotransferase, AST aspartate aminotransferase
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The serum ApoA5 levels were decreased in HBV patients
The serum ApoA5 levels in the HBV patients and healthy
individuals were measured by ELISA. The results showed
that the ApoA5 concentration was 196.4 ± 28.7 μg/L in
the healthy individuals and 104.5 ± 18.3 μg/L in the HBV
patients. The statistical analysis results showed that the
ApoA5 levels were significantly decreased in the HBV
patient group compared with that in the healthy control
group (P < 0.05, Fig. 2).
HBV inhibited ApoA5 promoter activity, mRNA and
protein expression
To investigate the molecular mechanism underlying the
inhibition of ApoA5 expression by HBV, we cotrans-
fected HepG2 cells with HBV infectious clone pHBV1.3
and the ApoA5 gene promoter pGL-ApoA5-LUC plas-
mid. Transfection with the empty vector pBlue-ks was
used as a control [8]. The efficiency of transfection was
estimated by the number of green fluorescence-emitting,
24–48 h after transfection, the total number of green
fluorescent cells revealed 55–65 % transfection effi-
ciency. The regulation of the ApoA5 promoter by HBV
was determined by measuring the luciferase activity. As
shown in Fig. 3a, the luciferase activity was significantly
reduced (105.6 ± 18.7 RUL/μg protein) after transfection
with pHBV1.3 compared with pBlue-ks transfection
(379.5 ± 26.4 RUL/μg protein). We further examined the
changes in ApoA5 mRNA and protein expression. The
results showed that the ApoA5 mRNA and protein ex-
pression levels were decreased after pHBV1.3 transfection
compared with pBlue-ks transfection (Fig. 3b, c, d and e).
HBV inhibited ApoA5 expression through its core gene
Eukaryotic expression plasmids containing all of the HBV
genes (pCMV-S, pCMV-E, pCMV-C, pCMV-X, and
pCMV-P) were cotransfected into HepG2 cells with the
ApoA5 gene promoter pGL3-ApoA5-LUC plasmid.
pCMV-tag2B was used as an empty control. 24–48 h
after transfected with pIRES2-EGFP, the transfection ef-
ficiency is 55–65 %. The regulatory effect of the pro-
teins on the ApoA5 gene promoter was examined by
measuring the luciferase activity. The results showed
that the HBV core gene had a significant inhibitory ef-
fect on the ApoA5 gene promoter, whereas the other
HBV genes did not have a significant regulatory effect
(Fig. 4a). Finally, we examined the changes in ApoA5
mRNA and protein expression. The results showed that
ApoA5 mRNA and protein expression was decreased
after transfection with the HBV core gene compared
with that after transfection with pCMV-tag2B (Fig. 4b,
c, d and e), suggesting that HBV might inhibit ApoA5
expression through its core gene.
Fig. 1 Comparison of ApoA5 mRNA and protein expression in HepG2 cells and HepG2.2.15 cells. a and b The relative levels of ApoA5 mRNA
between HepG2 and HepG2.2.15 cells were determined by RT-PCR. c and d ApoA5 protein expression in HepG2 and HepG2.2.15 cells was determined
by western blotting
Fig. 2 Comparison of serum ApoA5 levels between the healthy
individuals and HBV patients. The serum ApoA5 levels in 125
healthy individuals and 221 HBV patients were measured by
ELISA. *P < 0.005
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Discussion
In the present study, we investigated the differences in
ApoA5 expression in HepG2.2.15 and HepG2 cells. We
also examined the serum ApoA5 levels in HBV patients
and healthy controls. We found that HBV inhibited
ApoA5 expression both in vivo and in vitro. To investi-
gate the molecular mechanism by which HBV regulated
ApoA5 expression, we used the luciferase reporter gene
system to examine the regulatory effect of the infective
HBV clone pHBV1.3 on the ApoA5 gene promoter and
found that pHBV1.3 inhibited ApoA5 gene promoter ac-
tivity. pHBV1.3 also inhibited ApoA5 expression at both
the transcriptional and translational levels. Additionally,
we cotransfected all of the HBV genes with the ApoA5
gene promoter pGL3-ApoA5-LUC plasmid into HepG2
cells. By measuring the luciferase activity, we found that
the HBV core gene inhibited ApoA5 gene promoter activ-
ity. The RT-PCT and western blottingassays confirmed
that the core gene inhibited ApoA5 expression at the
mRNA and protein levels. Therefore, HBV may inhibit
ApoA5 expression through its core gene.
The liver is involved in the synthesis of almost all lipo-
proteins and the enzymes and proteins involved in lipo-
protein metabolism [9]. The liver is also the major site
of lipoprotein degradation and plays a very important
role in lipid metabolism [10, 11]. Studies have confirmed
that many viral infections change the blood lipid me-
tabolism [5, 12–14]. For example, serum high-density
lipoprotein (HDL), low-density lipoprotein (LDL), total
cholesterol (TC) and apolipoprotein B (ApoB) levels are
decreased in hepatitis C virus-infected patients [15–17].
Our previous studies also found that HBV inhibited the
synthesis and secretion of ApoB by inhibiting microsomal
triglyceride transfer protein (MTP) expression [18], and
the levels of serum ApoM was significantly elevated in pa-
tients as compared to healthy individuals, and enhanced
ApoM levels in HBV infection may in turn suppress HBV
replication [19]. Moreover, both Wang et al. and Jiang et
Fig. 3 HBV inhibited ApoA5 promoter activity, mRNA and protein expression. a Effect of HBV on ApoA5 promoter activity, *P < 0.005. HepG2 cells
were cotransfected with pHBV1.3 and the ApoA5 gene promoter pGL-ApoA5-LUC plasmid, and transfection with pBlue-ks was used as a control,
the luciferase activity was measured at 48 h post-transfection. b and c Effects of HBV on ApoA5 mRNA expression. HepG2 cells were transfected
with pHBV1.3 or pBlue-ks, 48 h after transfection, ApoA5 mRNA was determined by RT-PCR. d and e Effects of HBV on ApoA5 protein expression.
HepG2 cells were transfected with pHBV1.3 or pBlue-ks, 48 h after transfection, ApoA5 protein was determined by western blotting
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al. confirmed that HBV inhibited the synthesis and secre-
tion of ApoA1 in vivo and in vitro [20, 21].
ApoA5 has a stronger surface repulsion force and lipid
binding ability. Its concentration in plasma is very low,
but it plays an important role in in vivo blood lipid
metabolism. ApoA5 plays a role in elevating HDL
levels and is closely associated with hypertriglyceridemia
[22, 23]. In the present study, we found that the serum
ApoA5 content was decreased in HBV patients. Jiang et al.
examined the serum HDL-C content in HBV patients and
healthy controls and found that HDL-C was decreased in
HBV patients [20]. Because ApoA5 plays a role in elevat-
ing HDL-C, the decrease in the serum HDL-C content in
HBV patients may be related to the inhibition of ApoA5
expression by HBV.
Several researches have demonstrated a protective role
of HBV/HCV infection in the progression of atherosclerosis
because of the influence of the viruses on lipid metabolism
[24, 25] Our results are consistent with the conclusion,
which may shed new light on the effect of HBV infection in
the progression of atherosclerosis.
Conclusion
In summary, in the present study, we demonstrated that
HBV inhibited ApoA5 synthesis and secretion based on
both in vivo and in vitro experiments. However, elucidat-
ing the detailed molecular mechanism of how HBV core
gene inhibits the activity of ApoA5 gene promoter re-
quires further investigation.
Limitations and future study
The retrospective nature of this study is a limitation.
Firstly, we had no knowledge on the habitual diet of the
participants, which could influence lipids levels. However,
Fig. 4 HBV inhibited ApoA5 expression through its core gene. a Effect of HBV core gene on ApoA5 promoter activity, *P < 0.005. HepG2 cells
were transfected with pCMV-S, pCMV-E, pCMV-C, pCMV-X, pCMV-P and pCMV-tag2B, the luciferase activity was measured at 48 h post-transfection.
b and c Effects of HBV core gene on ApoA5 mRNA expression. HepG2 cells were transfected with pCMV-C or pCMV-tag2B, 48 h after transfection,
ApoA5 mRNA was determined by RT-PCR. d and e Effects of HBV core gene on ApoA5 protein expression. HepG2 cells were transfected with pCMV-C
or pCMV-tag2B, 48 h after transfection, ApoA5 protein was determined by western blotting
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it seems unlikely that the HBV patients would have had a
diet that differed substantially from that of the healthy in-
dividuals. Secondly, the role of anti-HBV drugs on the
serum ApoA5 levels were not considered. Thirdly, it is dif-
ficult to avoid a data bias from the analysis because of
derandomization and the sample size. Therefore, large
scale studies are needed for future prospective research to
determine the influence of the factors mentioned above
on the serum ApoA5 levels.
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